China Isotope & Radiation Corp

China Isotope & Radiation Corp maintains a debt-to-equity ratio of 0.52, indicating a relatively conservative capital structure. The company's liquidity position is characterized by a current ratio of 1.76, suggesting it has sufficient short-term assets to cover its liabilities. However, the firm's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 6.26% and a return on assets (ROA) of 2.08%. These figures are below the industry median for ROE and ROA, which are typically higher for firms in the medical equipment and supplies sector. The company's operating margin is 14.73%, and its net margin is 4.56%, both of which are below the industry median, indicating that the firm is underperforming in terms of profitability relative to its peers. The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed. This geographic concentration increases exposure to local economic and regulatory risks. The firm operates in a single business segment, which limits diversification and exposes it to sector-specific volatility. Looking ahead, the company is expected to grow revenue by approximately 10.6% year-over-year, from 7.19 billion CNY to 7.95 billion CNY. EBIT is projected to increase by 18.2% to 1.25 billion CNY, while EPS is expected to rise by 13.5% to 1.55 CNY. These growth rates are in line with the industry average, but the firm's ability to sustain this pace will depend on its capacity to manage costs and expand its market share. The company faces moderate liquidity risk due to its negative net cash position and a debt load that exceeds its cash reserves. While the firm's dilution risk is currently low, the risk assessment notes that the company may need to raise additional capital to fund operations or expansion, which could lead to share dilution. No recent equity issuance or dilution events have been reported, but the firm's capital structure suggests a potential need for future financing. Recent filings and transcripts indicate that the company is focused on expanding its product portfolio and improving operational efficiency. Management has emphasized the importance of R&D in developing new medical technologies and enhancing existing products. The firm has also expressed interest in exploring new markets, although no specific international expansion plans have been disclosed.